Zydus Lifesciences gets final approval to market Topiramate Extended-Release Capsules

01 Dec 2022 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy XR Extended-Release capsules).

Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy. It may also be used to prevent migraine headaches. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

Topiramate Extended-Release capsule had annual sales of $68.8 million in the United States according to IQVIA data (IQVIA MAT September 2022). The group now has 335 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04 (as of September 30, 2022).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

924.35 -7.10 (-0.76%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×